All studies
RecruitingTherapeutic exploratory (Phase II)Interventional

A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Atopic Dermatitis (COMPASS 2-AD)

Atopic dermatitis, commonly known as eczema, is a long-term condition that makes skin dry, red, itchy, and irritated. While treatments exist, they do not work well for everyone, leaving many people in need of better options. This Phase 2 study is testing an experimental medicine called BFB759. Adults joining the trial will be split by chance into three groups. Two groups will take different doses of BFB759, while one group will take a dummy medicine with no active ingredients (a placebo). Neither you nor your doctor will know which one you receive. Over 16 weeks, doctors will monitor how clear your skin becomes, how much the eczema shrinks, and whether your itching improves. They will also carefully track any side effects to ensure the medicine is safe and well tolerated. The findings will help researchers understand if BFB759 could become a useful new eczema treatment.

At a glance

Status
Recruiting
Phase
Therapeutic exploratory (Phase II)
Sponsor
Bluefin Biomedicine Inc.
Enrolment target
116
Start
31 Oct 2025

What is this study about?

Atopic dermatitis is the most common form of eczema in the UK. It causes dry, cracked, and very itchy skin that can flare up unpredictably. For many people, severe itching can lead to broken sleep, emotional distress, and difficulties with daily work or social activities. While moisturisers and steroid creams help many, some people still struggle to keep their symptoms under control.

This clinical trial, called COMPASS 2-AD, is testing a new experimental medicine called BFB759. It is a Phase 2 trial, which means the drug has already been tested in a small number of people, and researchers now want to see how well it works in a larger group. The study is also testing two different doses to discover which amount works best while causing the fewest side effects.

To find out if BFB759 truly works, researchers are comparing it to a 'placebo'—a dummy treatment that looks identical but contains no active medicine. Over 16 weeks of treatment, doctors will measure how much your skin improves using standard medical scoring systems. They will also look at how quickly it calms itchiness. Studies like this are an essential step in finding new, effective treatments for long-term skin conditions.

Key takeaways

  • Tests a new medicine called BFB759 for atopic dermatitis (eczema).
  • Open to adults aged 18 and over with active eczema.
  • Compares two different doses of BFB759 against a dummy treatment (placebo).
  • Treatment lasts for 16 weeks with regular clinic check-ups.
  • Aims to reduce skin inflammation, redness, and severe itching.
  • Participation is completely optional, and you can withdraw at any time.

Who may be eligible?

This trial is open to adults aged 18 and older who have been diagnosed with atopic dermatitis (eczema). Both men and women can take part.

To be suitable, your eczema usually needs to be active and covering a noticeable amount of your body. This allows doctors to measure whether the medicine is making a real difference to your skin.

You may not be able to take part if you are currently using certain strong eczema medicines, such as specific tablets or injections that affect the immune system. People with other skin conditions that could interfere with the results, or those with serious medical problems, may also be excluded. A doctor at the trial clinic will review your full medical history to confirm if joining is safe for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with atopic dermatitis (eczema).
  3. My eczema is currently active, red, or itchy.
  4. I can attend regular clinic appointments over roughly 4 to 5 months.
  5. I am willing to follow the study doctor's guidance on which skin treatments I can use.
Answer every question to see your result.

What does participation involve?

Taking part involves taking the study medication for 16 weeks, alongside a screening period before you start and check-ups afterwards. You will be randomly assigned to receive either a higher dose of BFB759, a lower dose of BFB759, or a placebo. You will need to visit the hospital or study clinic regularly throughout the trial. During these visits, the study team will examine your skin, measure your blood pressure, take blood and urine samples, and ask you to rate your daily itching using simple number scales. The total duration of your involvement is typically around four to five months.

Potential risks and benefits

You might experience an improvement in your eczema symptoms, though this cannot be guaranteed, especially if you are assigned to the placebo group. You will also receive thorough, regular health checks from skin specialists. However, as with any experimental drug, there is a risk of side effects, some of which may not yet be known. You may also experience mild bruising or discomfort from routine blood tests. Taking part is entirely voluntary, and you are free to stop and leave the trial at any time without your regular NHS care being affected.

Locations (5)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Poland
  • —
    Unverified
    Bulgaria
  • —
    Unverified
    Germany
  • —
    Unverified
    Czechia
  • —
    Unverified
    Spain

Common questions

What is a placebo and why is it used?

A placebo looks just like the real medicine but has no active drug inside. It allows doctors to see if skin improvements are truly caused by BFB759 rather than other factors.

Will I know which treatment I am receiving?

No. This is a 'double-blind' trial, meaning neither you nor your study doctor will know whether you are taking BFB759 or the placebo until the trial is finished.

How long will I be in the study?

The main treatment period lasts 16 weeks, but with initial health checks and final safety visits, total participation usually lasts around four to five months.

Do I have to pay to take part?

No, all study medicines, tests, and clinic appointments are free. Many trials also offer reimbursement for reasonable travel expenses to and from the clinic.

Can I carry on using my regular moisturisers?

Basic, gentle moisturisers are usually allowed or provided during the study, but your study team will give you clear instructions on which creams are permitted.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-c…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.